Calciphylaxis with normal renal and parathyroid function: Not as rare as previously believed

Archives of Dermatology

Volumn 145, Issue 4, 2009, Pages 451-458

  Kalajian, Andrew H ^a,e   Malhotra, Paula S ^b   Callen, Jeffrey P ^a   Parker, Lynn P ^c,d  

^a Division of Dermatology   (Japan)

^b Department of Medicine ^*

^c Division of Gynecologic Oncology   (Turkey)

^d UNIVERSITY OF LOUISVILLE   (United States)

^e University of Louisville School of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CINACALCET; CORTICOSTEROID; ENOXAPARIN; ERGOCALCIFEROL; PARATHYROID HORMONE; PHENPROCOUMON; SEVELAMER; SODIUM THIOSULFATE; WARFARIN;

ADULT; ANAMNESIS; ANTICOAGULATION; ANTIMICROBIAL THERAPY; ARTICLE; CALCINOSIS; CANCER CHEMOTHERAPY; CANCER REGRESSION; CASE REPORT; DIFFERENTIAL DIAGNOSIS; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ENDOMETRIUM CARCINOMA; FEMALE; HISTOPATHOLOGY; HUMAN; HYPOALBUMINEMIA; INFECTION; KIDNEY FUNCTION; LIVER CIRRHOSIS; MALIGNANT NEOPLASTIC DISEASE; MICROTHROMBUS; OBESITY; PARATHYROID FUNCTION; PHYSICAL EXAMINATION; PRIORITY JOURNAL; PROTEIN C DEFICIENCY; PROTEIN S DEFICIENCY; PURPURA; RISK FACTOR; SKIN BIOPSY; SKIN NECROSIS; SKIN ULCER; VASCULITIS; WEIGHT REDUCTION;

CALCIPHYLAXIS; DIAGNOSIS, DIFFERENTIAL; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; MIDDLE AGED; PARATHYROID DISEASES; RENAL INSUFFICIENCY; RISK FACTORS; SKIN DISEASES, VASCULAR;

EID: 65349154510     PISSN: 0003987X     EISSN: 15383652     Source Type: Journal    
DOI: 10.1001/archdermatol.2008.602     Document Type: Article

References (49)

1. Bolognia JL, Jorizzo JL, Rapini RP, eds. Dermatology. St Louis, MO: Mosby Year Book Inc; 2008:654-655.
2. Elder DE, Elenitsas R, Johnson BL, Murphy GF, eds. Lever's Histopathology of the Skin. Philadelphia, PA: Lippincott Williams & Wilkins; 2005:238.
3. Robson KJ, Piette WW. The presentation and differential diagnosis of cutaneous vascular occlusion syndromes. Adv Dermatol. 1999;15:153-182.
4. Fine A, Zacharias J. Calciphylaxis is usually non-ulcerating: risk factors, outcome, and therapy. Kidney Int. 2002;61(6):2210-2217.
5. Weenig RH, Sewell LD, Davis MD, McCarthy JT, Pittelkow MR. Calciphylaxis: natural history, risk factor analysis, and outcome. J Am Acad Dermatol. 2007; 56(4):569-579.
6. Guldbakke KK, Khachemoune A. Calciphylaxis. Int J Dermatol. 2007;46(3):231-238.
7. Mathur RV, Shortland JR, Nahas AM. Calciphylaxis. Postgrad Med J. 2001;77(911): 557-561.
8. Arch-Ferrer JE, Beenken SW, Rue LW, Bland KI, Diethelm AG. Therapy for calciphylaxis: an outcome analysis. Surgery. 2003;134(6):941-945.
9. Oh DH, Eulau D, Tokugawa DA, McGuire JS, Kohler S. Five cases of calciphylaxis and a review of the literature. J Am Acad Dermatol. 1999;40(6, pt 1):979-987.
10. Selye H, Gabbiani G, Strebel R. Sensitization to calciphylaxis by endogenous parathyroid hormone. Endocrinology. 1962;71:554-558.
11. Selye H. Generalities: brief characterization of calciphylaxis. In: Calciphylaxis. Chicago, IL: University of Chicago Press; 1962:1-36.
12. Selye H. Topical calciphylaxis. In: Calciphylaxis. Chicago, IL: University of Chicago Press; 1962:37-82.
13. Parfitt AM. Soft-tissue calcification in uremia. Arch Intern Med. 1969;124(5):544-556.
14. Owda A, Elhwaris H, Narra S, Towery H, Osama S. Secondary hyperparathyroidism in chronic hemodialysis patients: prevalence and race. Ren Fail. 2003; 25(4):595-602.
15. Kuzela DC, Huffer WE, Conger JD, Winter SD, Hammond WS. Soft tissue calcification in chronic dialysis patients. Am J Pathol. 1977;86(2):403-424.
16. Angelis M, Wong LL, Myers SA, Wong LM. Calciphylaxis in patients on hemodialysis: a prevalence study. Surgery. 1997;122(6):1083-1090
17. Budisavljevic MN, Cheek D, Ploth DW. Calciphylaxis in chronic renal failure. J Am Soc Nephrol. 1996;7(7):978-982.
18. Weenig RH. Pathogenesis of calciphylaxis: Hans Selye to nuclear factor κ-B. J Am Acad Dermatol. 2008;58(3):458-471
19. Ahmed S, O'Neil KD, Hood AF. Calciphylaxis is associated with hyperphosphatemia and increased osteopontin expression by vascular smooth muscle cells Am J Kidney Dis. 2001;37(6):1267-1276.
20. BleyerAJ, Choi M, Igwemezie B, de la Torre E, White WL. A case control study of proximal calciphylaxis. Am J Kidney Dis. 1998;32(3):376-383
21. Mazhar AR, Johnson RJ, Gillen D, et al. Risk factors and mortality associated with calciphylaxis in end-stage renal disease. Kidney Int. 2001;60(1):324-332
22. Golitz LE, Field JP. Metastatic calcification with skin necrosis. Arch Dermatol 1972;106(3):398-402
23. Fader DJ, Kang S. Calciphylaxis without renal failure. Arch Dermatol. 1996;132 (7):837-838
24. Mastruserio DN, Nguyen EO, Nielsen T, Hessel A, Pellegrini AE. Calciphylaxis associated with metastatic breast carcinoma. J Am Acad Dermatol. 1999;41(2, pt 2):295-298
25. Goyal S, Huhn KM, ProvostTT. Calciphylaxis in a patient without renal failure or elevated parathyroid hormone: possible aetiological role of chemotherapy. Br J Dermatol. 2000;143(5):1087-1090
26. Riegert-Johnson DL, Kaur JS, Pfeifer EA. Calciphylaxis associated with cholangiocarcinoma treated with low-molecular weight heparin and vitamin K. Mayo Clin Proc. 2001;76(7):749-752.
27. Lim SPR, Batta K, Tan B. Calciphylaxis in a patient with alcoholic liver disease in the absence of renal failure. Clin Exp Dermatol. 2003;28(1):34-36.
28. KorkmazC, DundarE, Zybaroglu I. Calciphylaxis in a patient with rheumatoid arthritis without renal failure and hyperparathyroidism: the possible role of longterm steroid use and protein S deficiency. Clin Rheumatol. 2002;21(1):66-69.
29. Banky JP, Dowling JP, Miles C. Idiopathic calciphylaxis. Australas J Dermatol 2002;43(3):190-193.
30. Kutlu NO, Aydin NE, Aslan M, BulutT, Ozgen U. Malignant melanoma of the soft parts showing calciphylaxis. PediatrHematol Oncol. 2003;20(2):141-146
31. Munavalli G, ReisenauerA, Moses M, Kilroy S, ArbiserJL. Weight loss-induced calciphylaxis: potential role of matrix metalloproteinases. J Dermatol. 2003 30(12):915-919
32. Bosler DS, Amin MB, Gulli F, Malhotra RK. Unusual case of calciphylaxis associated with metastatic breast carcinoma. Am J Dermatopathol. 2007;29(4) 400-403
33. Brouns K, Verbeken E, Degreef H, Bobbaers H, Blockmans D. Fatal calciphylaxis in two patients with giant cell arteritis. Clin Rheumatol. 2007;26(5):836-840.
34. Chavel SM,TaraszkaKS,SchafferJV, LazovaR, SchechnerJS. Calciphylaxis associated with acute, reversible renal failure in the setting of alcoholic cirrhosis J Am Acad Dermatol. 2004;50(5)(suppl):S125-S128
35. Heit JA, Silverstein MD, Mohr DN, Petterson TM, O'Fallon M, Melton LJ III Risk factors for deep vein thrombosis and pulmonary embolism: a populationbased case-control study. Arch Intern Med. 2000;160(6):809-815.
36. Maxwell SRJ, Moots RJ, Kendall MJ. Corticosteroids: do they damage the cardiovascular system? Postgrad Med J. 1994;70(830):863-870.
37. Hofbauer LC, Gori F, Riggs BL, etal. Stimulation of osteoprotegerin ligand and inhibition of osteoprotegerin production by glucocorticoids in human osteoblastic lineage cells: potential paracrine mechanisms of glucocorticoid-induced osteoporosis. Endocrinology. 1999;140(10):4382- 4389
38. Huang L, Xu J, Kumta SM, Zheng MH. Gene expression of glucocorticoid receptor a and pin giant cell tumour of bone: evidence of glucocorticoid- stimulated osteoclastogenesis by stromal-like tumour cells. Mol Cell Endocrinol. 2001 181(1-2):199-206
39. Price PA, Faus SA, Williamson MK. Warfarin causes rapid calcification of the elastic lamellae in rat arteries and heartvalves. Arterioscler Thromb Vasc Biol. 1998; 18(9):1400-1407
40. Mehta RL, Scott G, Sloand JA, Francis CW. Skin necrosis associated with acquired protein C deficiency in patients with renal failure and calciphylaxis. Am J Med. 1990;88(3):252-257
41. Smeeth L, Cook C, Thomas S, Hall AJ, Hubbard R, Vallance P. Risk of deep vein thrombosis and pulmonary embolism after acute infection in a community setting Lancet. 2006;367(9516):1075-1079
42. Goli AK, Goli SA, Shah LS, Byrd RP Jr, RoyTM. Calciphylaxis: a rare association with alcoholic cirrhosis: are deficiencies in protein C and S the cause? South Med J. 2005;98(7):736-739.
43. Almirall J,PoboA, BernaL. Post-infectious acute renal failure due to calciphylaxis- when processes go the wrong way round. J Nephrol. 2004;17(4):575-579
44. Robinson MR, Augustine JJ, Korman NJ. Cinacaletforthe treatment of calciphylaxis. Arch Dermatol. 2007;143(2):152-154.
45. Sharma A, Wright EB, Rustom R. Cinacalcet as an adjunct in successful treatment of calciphylaxis. Br J Dermatol. 2006;155(6):1295-1297
46. Guerra G, Shah RC, Ross EA. Rapid resolution of calciphylaxis with intravenous sodium thiosulfate and continuous venovenous haemofiltration using low calcium replacement fluid: case report. Nephrol Dial Transplant. 2005;20(6):1260-1262.
47. Baker BL, Fitzgibbons CA, BuescherLS. Calciphylaxis responding to sodium thiosulfate therapy. Arch Dermatol. 2007;143(2):269-270.
48. Holick MF. Vitamin D deficiency. N Engl J Med. 2007;357(3):266-281
49. Ball CL, Tobler K, Ross BC, Connors MR, Lyon ME. Spurious hyperphosphatemia due to sample contamination with heparinized saline from an indwelling catheter. Clin Chem Lab Med. 2004;42(1):107-108.